LYEL LYELL IMMUNOPHARMA INC revenue, earnings and financials

For the quarter ended June 30, 2026, LYELL IMMUNOPHARMA INC reported revenue of $4.00K (down 50.0% from a year earlier), net income of −$44.8M and diluted EPS of −$1.92; over the last four quarters revenue was $27.0K and net income −$248M; for the fiscal year ended December 2025 revenue was $36.0K, down 41.0% on the year before.

LYEL annual revenue and earnings

• Fiscal year ended Dec 2025: revenue $36.0K, gross profit n/a, operating income −$269M, net income −$274M (margin -762355.6%), EPS −$16.06
• Fiscal year ended Dec 2024: revenue $61.0K, gross profit n/a, operating income −$359M, net income −$343M (margin -562285.2%), EPS −$26.23
• Fiscal year ended Dec 2023: revenue $130K, gross profit n/a, operating income −$247M, net income −$235M (margin -180486.2%), EPS −$18.70
• Fiscal year ended Dec 2022: revenue $84.7M, gross profit n/a, operating income −$187M, net income −$183M (margin -216.2%), EPS −$0.74
• Fiscal year ended Dec 2021: revenue $10.7M, gross profit n/a, operating income −$215M, net income −$250M (margin -2349.5%), EPS −$1.84

LYEL quarterly revenue and earnings

• Quarter ended Jun 30, 2026: revenue $4.00K (down 50.0% year over year), net income −$44.8M, EPS −$1.92
• Quarter ended Mar 31, 2026: revenue $2.00K (down 71.4% year over year), net income −$24.2M, EPS −$1.10
• Quarter ended Dec 31, 2025 (from the annual report): revenue $6.00K (down 45.5% year over year), net income −$141M, EPS −$7.50
• Quarter ended Sep 30, 2025: revenue $15.0K (down 55.9% year over year), net income −$38.8M, EPS −$2.13
• Quarter ended Jun 30, 2025: revenue $8.00K (down 38.5% year over year), net income −$42.7M, EPS −$2.89
• Quarter ended Mar 31, 2025: revenue $7.00K (up 133.3% year over year), net income −$52.2M, EPS −$3.54
• Quarter ended Dec 31, 2024 (from the annual report): revenue $11.0K (down 15.4% year over year), net income −$192M, EPS −$18.92
• Quarter ended Sep 30, 2024: revenue $34.0K (up 36.0% year over year), net income −$44.6M, EPS −$3.48
• Quarter ended Jun 30, 2024: revenue $13.0K (down 51.9% year over year), net income −$45.8M, EPS −$3.59
• Quarter ended Mar 31, 2024: revenue $3.00K (down 95.4% year over year), net income −$60.7M, EPS −$0.24
• Quarter ended Dec 31, 2023 (from the annual report): revenue $13.0K (down 100.0% year over year), net income −$52.9M, EPS −$17.97
• Quarter ended Sep 30, 2023: revenue $25.0K (up 733.3% year over year), net income −$50.9M, EPS −$0.20
• Quarter ended Jun 30, 2023: revenue $27.0K (down 99.9% year over year), net income −$63.9M, EPS −$0.26
• Quarter ended Mar 31, 2023: revenue $65.0K (down 88.2% year over year), net income −$67.0M, EPS −$0.27
• Quarter ended Dec 31, 2022 (from the annual report): revenue $48.4M (up 1614.6% year over year), net income −$8.40M, EPS −$0.03
• Quarter ended Sep 30, 2022: revenue $3.00K (down 99.9% year over year), net income −$70.3M, EPS −$0.28
• Quarter ended Jun 30, 2022: revenue $35.7M (up 1260.0% year over year), net income −$36.3M, EPS −$0.15
• Quarter ended Mar 31, 2022: revenue $553K (down 77.4% year over year), net income −$68.1M, EPS −$0.28
• Quarter ended Dec 31, 2021 (from the annual report): revenue $2.82M, net income −$83.7M, EPS $3.02
• Quarter ended Sep 30, 2021: revenue $2.76M, net income −$48.9M, EPS −$0.20

LYEL cash flow, buybacks and dividends

• Fiscal year ended Dec 2025: operating cash flow −$150M, share buybacks n/a
• Fiscal year ended Dec 2024: operating cash flow −$162M, share buybacks n/a
• Fiscal year ended Dec 2023: operating cash flow −$164M, share buybacks n/a
• Fiscal year ended Dec 2022: operating cash flow −$170M, share buybacks $0
• Fiscal year ended Dec 2021: operating cash flow −$126M, share buybacks $0

LYEL balance sheet

• Jun 30, 2026: cash $73.0M, total assets $311M, total liabilities $77.3M, shareholders' equity $234M
• Mar 31, 2026: cash $90.8M, total assets $351M, total liabilities $77.0M, shareholders' equity $274M
• Dec 31, 2025: cash $60.2M, total assets $340M, total liabilities $91.9M, shareholders' equity $248M
• Sep 30, 2025: cash $124M, total assets $408M, total liabilities $78.8M, shareholders' equity $329M
• Jun 30, 2025: cash $98.8M, total assets $385M, total liabilities $86.5M, shareholders' equity $299M
• Mar 31, 2025: cash $120M, total assets $430M, total liabilities $93.3M, shareholders' equity $337M
• Dec 31, 2024: cash $106M, total assets $491M, total liabilities $108M, shareholders' equity $383M
• Sep 30, 2024: cash $100M, total assets $619M, total liabilities $88.5M, shareholders' equity $531M

What is LYEL's revenue?

LYELL IMMUNOPHARMA INC reported $27.0K of revenue over its last four quarters, through June 30, 2026.

Is LYEL profitable?

No. LYELL IMMUNOPHARMA INC lost $248M over the last four quarters.

What is LYEL's EPS?

Diluted earnings per share over the last four quarters were −$12.65; −$1.92 in the latest quarter.

LYEL ownership and insider trades · All stocks